Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Revenue projections:

With BDX's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio	0.865000
forwardPE	13.386216
debtToEquity	68.840000
earningsGrowth	-0.314000
revenueGrowth	0.054000
grossMargins	0.469360
operatingMargins	0.157330
trailingEps	5.750000
forwardEps	13.302490

BDX's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
BDX's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
Becton, Dickinson and Company's negative gross and operating margins highlight that the company is incurring losses, unable to generate profit from production or operations. This could be a sign of rising costs or declining revenues, impacting its financial outlook.
With a forward EPS greater than its trailing EPS, Becton, Dickinson and Company is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

BDX's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

BDX saw 25 transactions in which shares were sold with market price at 159.17995239257812.There were 1 buy transactions of BDX stock, with market price at 151.3364715576172 per share.The list of insider trades lacks a strong directional signal, offering no compelling insights into the company's current or future state.

Recommendation changes over time:

Analysts have been favoring BDX with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning BDX as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.